Screening Chest CT to Detect Interstitial Lung Disease in Systemic Sclerosis

项目概要/摘要 候选人：伯恩斯坦博士是哥伦比亚大学流变学系的医学助理教授 大学她是一名临床研究者，共有12篇和7篇第一作者原创研究出版物， 来自关节炎基金会和KL 2的资金，以及来自流变学研究的当前资金 基金会她拥有临床和转化研究硕士学位。她的长期职业目标是 成为风湿病学的独立研究者，领导临床和流行病学 系统性硬化症（SSc）中早期间质性肺病（ILD）的研究，以及谁开发和测试 预防SSc中ILD的干预措施。职业发展计划：伯恩斯坦博士和她的导师们 制定了职业发展计划，旨在在K23奖励期结束时实现独立， 包括先进的流行病学方法和统计建模，定性和定量肺 成像、临床试验和多中心研究。这些新的技能和知识将使伯恩斯坦博士 作为一名独立的临床和流行病学研究者，专注于SSc中ILD的预防， 并在K23的第四年提交竞争性R 01申请。环境：伯恩斯坦博士 受保护的时间，设施，资源和医学系的专家支持，以完成 指导K23中概述的研究和职业发展活动。医学系和 流变学部门保证至少75%的时间用于研究和事业 发展她经常有机会与其他研究人员进行智力交流，包括 有机会出席和出席与她的领域有关的大量经常性会议和研讨会 研究。她还将在哥伦比亚大学梅尔曼公共学院从事相关课程的工作 健康研究：在大卫莱德勒博士和琼博士领导的专家导师团队的指导下， 伯恩斯坦博士将对220名新转诊的SSc成人进行一项双中心前瞻性队列研究 来实现她的目标。本研究的中心假设是，SSc中筛查检出的ILD在生物学上 尽管没有症状，但具有临床相关性，因为它（1）与ILD的生物标志物相关 以及（2）在临床症状和功能限制的发作之前，因此可以代表“窗口 机会”的干预。在目标1中，伯恩斯坦博士将进行一项横断面研究， SSc中筛查检出ILD的患病率、临床特征和生物标志物特征。在目标2中，她将执行 纵向研究，以检查SSc中筛查检出的ILD的进展。执行此K23指导 研究和获得先进的流行病学方法和统计建模，定性和 定量肺成像，临床试验和多中心研究将使她成为一个成功的 独立调查员

Project Summary/Abstract Candidate: Dr. Bernstein is Assistant Professor of Medicine in the Division of Rheumatology at Columbia University. She is a clinical investigator with 12 total and 7 first-author original research publications, previous funding from the Arthritis Foundation and a KL2, and current funding from the Rheumatology Research Foundation. She has a Master’s Degree in Clinical and Translational Investigation. Her long-term career goal is to become an independent investigator in rheumatology who leads both clinical and epidemiological investigations of early interstitial lung disease (ILD) in systemic sclerosis (SSc), and who develops and tests interventions for the prevention of ILD in SSc. Career Development Plan: Dr. Bernstein and her mentors have crafted a career development plan intended to lead to independence by the end of the K23 award period, including training in advanced epidemiological methods and statistical modeling, qualitative and quantitative lung imaging, and clinical trials and multicenter studies. These new skills and knowledge will allow Dr. Bernstein to pursue a career as an independent clinical and epidemiologic investigator focused on prevention of ILD in SSc, and to submit a competitive R01 application during the fourth year of the K23. Environment: Dr. Bernstein has the protected time, facilities, resources, and expert support of the Department of Medicine to accomplish the mentored research and career development activities outlined in the K23. The Department of Medicine and Division of Rheumatology have guaranteed at least 75% protected time to devote to research and career development. She has regular opportunities for intellectual interactions with other investigators, including the opportunity to attend and present at a large number of recurring conferences and seminars relevant to her area of research. She will also engage in relevant coursework at the Columbia University Mailman School of Public Health. Research: Under the guidance of her expert mentorship team, led by Drs. David Lederer and Joan Bathon, Dr. Bernstein will perform a two-center prospective cohort study of 220 newly referred adults with SSc to achieve her Aims. The central hypothesis of this study is that screen-detected ILD in SSc is both biologically and clinically relevant, despite the absence of symptoms, because it (1) is associated with biomarkers of ILD and (2) precedes the onset of clinical symptoms and functional limitation and may therefore represent a “window of opportunity” for intervention. In Aim 1, Dr. Bernstein will conduct a cross-sectional study to establish the prevalence, clinical features, and biomarker profile of screen-detected ILD in SSc. In Aim 2, she will perform a longitudinal study to examine the progression of screen-detected ILD in SSc. Performing this K23 mentored research and obtaining training in advanced epidemiological methods and statistical modeling, qualitative and quantitative lung imaging, and clinical trials and multicenter studies will position her to become a successful independent investigator.